Apimeds Pharmaceuticals US, Inc.
Close on Oct 19, 2026
- Market cap
- $6.00M
- P/E (TTM)
- –
- Dividend yield
- –
About Apimeds Pharmaceuticals US
Pharmaceutical Preparations, SIC 2834
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on the development of Apitox, an intradermally administered purified honeybee venom-based biologic. The company develops therapies designed to treat inflammation and manage pain symptoms associated with knee osteoarthritis and multiple sclerosis. Operating through wholly owned subsidiaries Lokahi Therapeutics, Inc. and MindWave Innovations Inc., the business directs its offerings toward clinical patient populations suffering from chronic inflammatory and neurodegenerative joint or central nervous system disorders. Additionally, through educational initiatives such as the ai² Futures Lab, the organization collaborates with university students to evaluate therapeutic assets.
The company focuses its primary clinical development activities within the United States. Its operations rely on prior clinical trial data and proprietary extraction methods established in South Korea. The company maintains its principal executive offices in Matawan, New Jersey.
Summary of the business section of Apimeds Pharmaceuticals US's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Apimeds Pharmaceuticals US, Inc.
- Founded
- 1989
- Headquarters
- Matawan, NJ
- Address
- 100 Matawan Rd, Suite 325 07747
- Phone
- (848) 201-5010
- Employees
- 9, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kreit & Chiu CPA LLP, New York, New York
Stock & identifiers
- Ticker
- APUS
- Exchange
- NYSE
- IPO date
- May 9, 2025
- Shares outstanding
- 2M, Aug 12, 2026
- Public float
- $7.81M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Aug 14, 2026; 1-for-10 reverse, Jul 24, 2026
- SEC CIK
- 1894525
- CUSIP
- 03771D102
- ISIN
- US03771D1028
- EIN
- 85-1099700
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Erik C. Emerson | Chief Executive Officer, Director | 750,000 |
| Christopher Kim | Chairman and CMO, Director | 277,500 |
| Mark Corrao | Chief Financial Officer | – |
| Bennett Weintraub | Director | – |
| Hankil Yoon | Director | – |
| Carol A. O'Donnell | Director | – |
| Elona Kogan | Director | – |
| Jakap Koo | Director | 643,885 |
Employees
Headcount reported in annual reports
“As of January 11, 2026, we had a total of 9 employees,”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 15, 2026 | Late filing | Notification of late filing |
| Apr 22, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 31, 2026 | Late filing | Notification of late filing |
| Feb 17, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 2, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 14, 2025 | Late filing | Notification of late filing |
| May 15, 2025 | Late filing | Notification of late filing |
| May 9, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 31, 2025 | Late filing | Notification of late filing |
| Mar 3, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |